E-MOTIVE early detection and treatment bundle,
does it really help with Reduced severe postpartum hemorrhage, laparotomy for bleeding, or death from bleeding after vaginal birth?
research showsThe grade is B with 76 points. E-MOTIVE randomized 80 hospitals, and among 98,722 participants in the source-verified primary analysis, severe postpartum hemorrhage, laparotomy for bleeding, or death from bleeding occurred in 794/48,678 (1.6%) versus 2,139/50,044 (4.3%), adjusted RR 0.40 (95% CI 0.32 to 0.50). It remains one confirmatory trial.
ads claimThis is not one drug. It combines objective early detection, uterine massage, uterotonics, tranexamic acid, intravenous fluid, examination and escalation, plus training and stocked carts. Verdict 1145 is B with 76 points for tranexamic acid, verdict 1455 is B with 77 points for oxytocin, verdict 1353 is B with 68 points for carbetocin, and verdict 2524 is B with 76 points for active management of the third stage; each asks a different question.
Useful facts when choosing a product
- MOTIVE stands for massage, oxytocics, tranexamic acid, intravenous fluids, verification/examination, and escalation.
- Intervention hospitals used calibrated drapes and control hospitals used uncalibrated study-measurement drapes.
- Medicines came from existing hospital procurement and local stocks.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.e-motive.UNK.severe-postpartum-hemorrhage-laparotomy-for-bleeding-or-death-from-bleeding-after-vaginal-birth.reduce.UNKUnknown > E-MOTIVE > Unknown > severe postpartum hemorrhage, laparotomy for bleeding, or death from bleeding after vaginal birth > Reduction claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
The trial randomized 80 hospitals in Kenya, Nigeria, South Africa, and Tanzania and analyzed 210,132 vaginal births at 78 hospitals. The randomized-period source-verified primary analysis included 98,722 participants. The article and NCT04341662 were cross-checked for the primary endpoint and comparisons. Births with missing primary-outcome data were excluded. The Bill & Melinda Gates Foundation funded the trial, and commercial suppliers had no role in design, analysis, or writing.
Why this is classified as B (76)
A large nonprofit-funded cluster trial substantially reduced direct severe bleeding, surgery, or death, but it remains one confirmatory trial and excluded missing-outcome births from the primary analysis, giving B with 76 points.
Counterpoint. Postpartum hemorrhage requires emergency institutional care; this is not a home-treatment bundle.
Rejudgment record. Cross-check applied — Cross-checked the NEJM report, protocol, and NCT04341662 for hospital randomization, primary-analysis count, prespecified composite, source verification, missing-outcome exclusion, and funding
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced severe postpartum hemorrhage, laparotomy, or death from bleeding | B | Rates were 1.6% versus 4.3%, adjusted RR 0.40. |
| Improved early detection and bundle adherence | B | Detection was 93.1% versus 51.1%, and bundle use 91.2% versus 19.4%. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gallos I, Devall A, Martin J, Middleton L, Beeson L, Galadanci H, Alwy Al-Beity F, Qureshi Z, Hofmeyr GJ, Moran N, Fawcus S, Sheikh L, Gwako G, Osoti A, Aswat A, Mammoliti KM, Sindhu KN, Podesek M, Horne I, Timms R, Yunas I, Okore J, Singata-Madliki M, Arends E, Wakili AA, Mwampashi A, Nausheen S, Muhammad S, Latthe P, Evans C, Akter S, Forbes G, Lissauer D, Meher S, Weeks A, Shennan A, Ammerdorffer A, Williams E, Roberts T, Widmer M, Oladapo OT, Lorencatto F, Bohren MA, Miller S, Althabe F, Gülmezoglu M, Smith JM, Hemming K, Coomarasamy A. 2023 E-MOTIVE | Parallel cluster-randomized trial of 80 hospitals in four countries | 80 hospitals randomized; 210,132 births at 78 hospitals; 98,722 in the randomized-period source-verified primary analysis (48,678/50,044) | Bill & Melinda Gates Foundation investment grant INV-001393 | Composite of severe postpartum hemorrhage, laparotomy for bleeding, or death from bleeding | 794/48,678 (1.6%) versus 2,139/50,044 (4.3%), adjusted RR 0.40 (95% CI 0.32 to 0.50), P<0.001 | Single large nonprofit-funded hard-outcome trial |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-15).
Final verification and publication gate: Codex · Evidence date: 2026-08-15 · Corrections: none
Cite this verdict
[Chamgap] E-MOTIVE early detection and treatment bundle x severe postpartum hemorrhage — Evidence Grade B·76. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/e-motive-early-detection-treatment-bundle-postpartum-hemorrhage/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.